|
Match
|
Document |
Document Title |
|
|
7618948 |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the...
|
|
|
7618947 |
Modulation of HIF-1 beta expression
Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of...
|
|
|
7618943 |
Fusion polypeptides, and use thereof in antivascular tumor therapy
The present invention relates to fusion polypeptides, comprising at least two peptides. The invention further relates to the use of these fusion proteins in antivascular therapy of neoplastic...
|
|
|
7618623 |
Hybrid adeno-retroviral vector for the transfection of cells
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid...
|
|
|
7615627 |
RNA interference mediated inhibition of aurorakinase B and its combinations as anticancer therapy
This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the...
|
|
|
7615541 |
siRNA targeting TIE-2
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7615540 |
Formulations comprising antisense nucleotides to connexins
A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site...
|
|
|
7615539 |
Nucleic acid-lipophilic conjugates
The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic...
|
|
|
7615538 |
Method for therapy of rheumatoid arthritis
The invention provides a method for therapy of rheumatoid arthritis, which comprises administering double-stranded oligonucleotide comprising the nucleotide sequence of 5′-TGAGTCA-3′ to a...
|
|
|
7615537 |
Methods for treating blood coagulation disorders
The present invention relates to a method of treating an individual having a blood coagulation defect (e.g., hemophilia A, hemophilia B), comprising administering to the individual an effective...
|
|
|
7612195 |
Retroviral vectors for delivery of interfering RNA
Provided herein are retroviral vectors for delivering interfering RNA into cells.
|
|
|
7612185 |
Nucleic acid biosensors
Sensors comprising aptazymes capable of detecting the presence and concentration of effectors, as well as methods of using such sensors, are disclosed.
|
|
|
7612046 |
Method for treating kidney disorders
The present invention relates to a cellular therapy of renal failure, i.e. preventing, delaying, and treating acute/chronic renal failure via the use of an effective dose of a substance capable of...
|
|
|
7612042 |
Methods for inhibiting heregulin and treating cancer
The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention...
|
|
|
7611843 |
Eubacterial tmRNA sequences and uses thereof
The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and...
|
|
|
7608707 |
siRNA targeting survivin
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene...
|
|
|
7608706 |
siRNA targeting ras-related nuclear protein
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7608705 |
Oligonucleotides, agents containing these oligonucleotides, and the use thereof
The invention relates to particular oligonucleotides, pharmaceutical agents that contain these oligonucleotides, and to the therapeutic use thereof. The oligonucleotides are, in particular, capable...
|
|
|
7608597 |
Methods and compositions for treating hepatitis C virus
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
|
|
|
7608422 |
Simian immunodeficiency virus (SIV) molecular clone encoding mutant gag gene lacking inhibitory/instability regions
Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host...
|
|
|
7608257 |
Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus...
|
|
|
7605252 |
siRNA targeting kinase insert domain receptor (KDR)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7605251 |
Compositions and methods for inhibiting expression of the PCSK9 gene
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having...
|
|
|
7605142 |
Expression of cyclin G1 in tumors
A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount...
|
|
|
7605141 |
Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof
Compositions containing purified nucleic acid wherein the nucleic acid acts as an antioxidant. Such compositions also include materials subject to oxidative damage such as antioxidants, vitamins,...
|
|
|
7605140 |
Regulation of angiogenesis with zinc finger proteins
Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation...
|
|
|
7605139 |
DNA cancer vaccines
A plurality of DNA cancer vaccines and their uses in treating cancer are disclosed. Genes encoding Mycobacterium bovis bacillus Calmette-Guérin ( M. bovis BCG) recombinant antigens and genes...
|
|
|
7605138 |
Nucleic acid compositions for stimulating immune responses
The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
|
|
|
7601700 |
Modulation of eIF4E expression
Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid...
|
|
|
7601699 |
Production of reprogrammed cells with restored potential
A method for treating cells and/or nuclear transfer units and/or stem cells in culture with such compounds, individually or in combinations, is described. The method results in a globally...
|
|
|
7601698 |
Polypeptide
The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least...
|
|
|
7601697 |
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The...
|
|
|
7601696 |
Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatment
Oct-1 is shown to be an oncoprotein because of its known role as an activator of the histone H2B gene and the importance of this gene during DNA synthesis. To determine the role of Oct-1 as an...
|
|
|
7598370 |
siRNA targeting polo-like kinase-1 (PLK-1)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7598229 |
Metastatic colorectal cancer vaccine
The invention relates to prophylactic and therapeutic vaccines for protecting individuals against metastatic colorectal cancer and for treating individuals who are suffering from metastatic...
|
|
|
7598228 |
Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1
A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding...
|
|
|
7598227 |
Modulation of apolipoprotein C-III expression
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein...
|
|
|
7598226 |
Compositions and methods for the therapy and diagnosis of breast cancer
Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic...
|
|
|
7598225 |
Generation of immune response to prostate-specific antigen (PSA)
We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA),...
|
|
|
RE40930 |
Porcine adenovirus type 3 genome
The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells...
|
|
|
7595388 |
siRNA targeting EPH receptor A3 (EPHA3)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7595387 |
Modified polynucleotides for reducing off-target effects in RNA interference
Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference...
|
|
|
7595306 |
Method of treating neurodegenerative disease
Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA...
|
|
|
7595305 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an...
|
|
|
7595304 |
Polymeric oligonucleotide prodrugs
Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed.
|
|
|
7595303 |
Genetic adjuvants for immunotherapy
The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of...
|
|
|
7595302 |
Nucleic acids useful for triggering tumor cell lethality
The invention relates to double-stranded nucleic acid fragments comprising a chemically modified backbone and at least 4-1000 bp, preferably 8-500 bp, and most preferably 16-200 bp. The disclosed...
|
|
|
7595301 |
Staple type oligonucleotide and drug comprising the same
Conventional oligonucleotides are opened at both ends and thereby unstable. Their stability against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes...
|
|
|
7592444 |
siRNA targeting myeloid cell leukemia sequence 1
Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia...
|
|
|
7592441 |
Liver cancer-related nucleic acids
Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that...
|